Krystal Biotech Reports Net Loss of $33.2 Million for Q2 2023

Krystal Biotech, Inc.(KRYS), a leading biotechnology com pany specializing in gene therapies, has released its financial results for the second quarter of 2023. The company reported a net loss of $33.2 million for the quarter, along with a significant increase in revenue compared to the same period in the previous year.

Net Loss Highlights

Krystal Biotech faced a net loss of $33.2 million for the second quarter of 2023. This loss reflects the company's continued investment in research and development, as well as general and administrative expenses. Despite the net loss, the company remains committed to advancing its innovative gene therapy pipeline.

Revenue Surge